Sarah Gordon Wild worked on Wall Street from 1986-2003, where her roles included being a biotechnology analyst at Greig Middleton, Kleinwort Grieveson, Hambrecht and Quist and Amerindo Investment Advisors. She was subsequently an analyst and portfolio manager at Lone Pine Capital where she focused on biotechnology, device and pharmaceutical companies. Sarah has a lifelong interest in how technology and healthcare products progress through research & development to commercialisation, and differences between the UK and US.
She now lives in the UK and has consulted in the Hedge Fund business. Sarah also serves on the Board of Lone Pine Capital Offshore Funds and Oxford Nanopore Technologies.